Compass Pathways

British psychedelic medicine company

📊 Rating

1 news mentions · 👍 0 likes · 👎 0 dislikes

📌 Topics

Pharmaceutical Innovation (1)
Mental Health Treatment (1)
Clinical Trials (1)
Regulatory Affairs (1)

🏷️ Keywords

Compass Pathways (1) · COMP360 (1) · Treatment-resistant depression (1) · Phase III trials (1) · TD Cowen Conference (1) · 25mg dose efficacy (1) · Regulatory approval (1) · Mental health innovation (1)

📖 Key Information

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA).

📰 Related News (1)

🇺🇸 Compass Pathways at TD Cowen Conference: Promising Data for Depression Drug (2026-03-03)

🔗 Entity Intersection Graph

People and organizations frequently mentioned alongside Compass Pathways:

🌐
Regulation · 1 shared articles
Phases of clinical research · 1 shared articles